Clinical trials: Mammographic Breast Density
Breast Cancer
Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density
It has been shown that women who have dense breasts have an increased risk of breast cancer compared with women whose breasts are less dense.
- Trial name
- NCT00418236
- Where
- 37 sites in United States, Argentina and 12 more
- Volunteers
- 400 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Mammographic Density
Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density
To evaluate the impact of a selective androgen receptor modulator combined with an aromatase inhibitor in reducing high mammographic breast density.
- Trial name
- NCT03264651
- Testing
- enobosarm
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- Havah Therapeutics Pty Ltd
Mammographic Density
A Single Dose Trial to Evaluate the Pharmacokinetics of Testosterone and Anastrozole
A single dose trial to evaluate the pharmacokinetics of testosterone and anastrozole from subcutaneous testosterone and anastrozole (T+Ai) in premenopausal women
- Trial name
- NCT03314298
- Testing
- testosterone anastrozole
- Where
- Australia
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Havah Therapeutics Pty Ltd
Mammographic Breast Density
Topical Endoxifen in Women
Karma CREME-1 consisted of 90 participants from the Karma Cohort. The major focus of the pilot trial was to estimate time to mammographic density change.
- Trial name
- CREME (NCT04616430)
- Testing
- Topical endoxifen
- Where
- Sweden
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Atossa Therapeutics, Inc.
Breast Neoplasms
MBI and Breast Tomosynthesis Screening Accuracies in Patients With Dense Breast Tissue
Primary: In women with heterogeneous or dense breast tissue (mammographic types 3 and 4), MBI (Molecular Breast Imaging) will detect more breast cancers and have greater sensitivity in detecting breast cancer than breast…
- Trial name
- NCT02013726
- Testing
- MBI Scan: The LumaGEM®, 3D Mammogram/Breast Tomosynthesis Scan: Selenia® Dimensions®
- Volunteers
- healthy volunteers welcome
- Sponsor
- Gamma Medica, Inc.
Osteoporosis
Study Evaluating Changes In Mammographic Breast Density
The objective of the study is to evaluate quantitative changes in mammographic breast density from baseline to 24 months in postmenopausal women receiving daily doses of either BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg…
- Trial name
- NCT00774267
- Testing
- BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg
- Where
- 26 sites in United States, Brazil and 2 more
- Volunteers
- 507 people
- Sponsor
- Pfizer
Mammographic Breast Density
Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue
A study to determine the efficacy of 8 mg/day (4 mg/breast) of BHR-700 gel compared to placebo for reducing breast tissue density in women identified as having dense breast tissue upon analysis of screening mammography.
- Trial name
- 4WARD (NCT03199963)
- Testing
- 4-OH tamoxifen
- Where
- 19 sites in United States, Germany and 1 more
- Volunteers
- 223 people
- Sponsor
- BHR Pharma, LLC